LDLR and familial hyperaldosteronism: The efficacy of PCSK9 gene therapy might be limited in FH patients that exhibit an LDLR mutation, since these patients already have affected LDL-C uptake by expressing less LDL receptors; however, clinical trials of PCSK9 antibodies in patients with heterozygous FH showed comparable LDL-lowering efficacy as in patients without FH [14,51].